Paper Details

  1. Home
  2. Paper Details

Comparison of two oral forms of erythromycin in the treatment of acute respiratory tract infections. A multicentre general practice study.

Author: BardenR, ColesS, MacklinJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Both enteric-coated pellets of erythromycin base and erythromycin ethylsuccinate tablets are highly effective in treating acute respiratory tract infections. In a single-blind, multicentre study of 1244 patients, both formulations showed similar efficacy, with about 90% of patients cured or improved after at least 5 days of treatment. Gastrointestinal symptoms were more frequent with erythromycin base and were the main reason for discontinuing treatment.
Paper Details　
Original Abstract of the Article :
A total of 1244 patients with acute upper or lower respiratory tract infection were randomized to receive, twice daily for 7 days, either capsules of enteric-coated pellets of erythromycin base at a dose of 1 g/day or erythromycin ethylsuccinate tablets at a dose of 2 g/day in a single-blind, multic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/030006058901700312

データ提供：米国国立医学図書館（NLM）

Erythromycin: Navigating the Desert of Respiratory Infections

[Acute respiratory tract infections (ARTIs)] are a common ailment that can disrupt daily life. This study compares the [efficacy and tolerability] of [two oral forms of erythromycin] in treating [ARTIs]. The researchers conducted a [single-blind, multicenter study] to evaluate the [clinical effectiveness] and [side effect profiles] of [erythromycin base and erythromycin ethylsuccinate] in patients with [ARTIs].

Finding the Right Oasis: Choosing the Right Erythromycin

This study finds that [both formulations of erythromycin are highly effective] in treating [ARTIs], with approximately [90% of patients showing improvement]. However, the researchers also note that [erythromycin base is associated with a higher incidence of gastrointestinal side effects] compared to [erythromycin ethylsuccinate]. This finding suggests that [clinicians should consider individual patient factors] when choosing the [most appropriate erythromycin formulation] to minimize [side effects].

Navigating the Side Effects: A Path to Relief

This study underscores the importance of [considering individual patient needs] when prescribing [erythromycin] for [ARTIs]. The researchers highlight the [potential gastrointestinal side effects] associated with [erythromycin base] and emphasize the need for [careful monitoring and patient education] to ensure [optimal treatment outcomes].

Dr.Camel's Conclusion

This study highlights the [efficacy and tolerability] of [two oral forms of erythromycin] in the treatment of [ARTIs]. It's like navigating a desert with different routes; choosing the right path can minimize the risk of [side effects] and lead to a [smoother journey] toward [recovery]. The findings provide valuable insights for [clinicians] to [make informed decisions] and [optimize treatment] for patients with [ARTIs].
Date :
  1. Date Completed 1989-10-11
  2. Date Revised 2017-02-14
Further Info :

Pubmed ID

2670633

DOI: Digital Object Identifier

10.1177/030006058901700312

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.